Democritus University of Thrace (DUTH)
In vivo and in vitro generation of tumor antigen-specific T cells using human CD34+ hematopoietic stem cells or engineered mature T cells
Abstract
dc:descriptionThe last few decades have seen an incredible boost in cancer research that has transformed the clinical reality. However, many patients still do not benefit from current clinical protocols. Can-cer immunotherapy that aims to engage the patient’s immune system in the fight against the dis-ease has emerged as a powerful supplement to standard-of-care treatments. Adoptive cell trans-fer (ACT) lies in the heart of cellular immunotherapies and involves the isolation, expansion, and rejuvenation of a patient’s T cells before reinfusion. Still, reintroduced T cells suffer from poor in vivo persistence and activity, whereas the highly immunosuppressive, adaptive micro-environment, especially of solid cancers, poses an obstacle to ACT’s success. Macrophages, which make up the majority of intratumoral immune cells and are a significant component of the tumor microenvironment (TME), can actively suppress the homing and activity of tumor-specific T cells. Aiming to reprogram the TME and enhance ACT therapies, we describe the generation of tumor-specific ‘armored’ T cells that are further engineered to secrete immuno-modulatory agents. We show that ‘armored’ T cells, producing soluble molecules that block the immunosuppressive cluster of differentiation 47 (CD47)/signal-regulatory protein α (SiRPα) ‘don’t eat me’ pathway, enhance the phagocytic capacity of mouse and human macrophages against human solid tumor targets in vitro and improve tumor control by adoptively transferred T cells in vivo. Furthermore, to achieve long-term antitumor immunity and prolong the in vivo potential of cellular therapies, we report the generation of tumor-specific T cells from genetical-ly engineered hematopoietic stem cells (HSCs) and explore the potential of the generated T cell progenitors in ACT therapy. Thus, our work expands upon established ACT-based methodol-ogies and introduces new cellular products with superior immunomodulatory, tumor-killing properties that can reshape the suppressive cancer microenvironment and mount effective anti-tumor immune responses.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stefanidis, Evangelos-Nektarios
- Στεφανίδης, Ευάγγελος-Νεκτάριος
Subjects
dc:subject × 22- Τ-λεμφοκύτταρα
- CD34 θετικά προγονικά αιμοποιητικά κύτταρα
- Ανοσοθεραπεία καρκίνου
- Θυμοποίηση in vitro
- Γενετική τροποποίηση με ιούς
- Συνδυαστική θεραπεία
- Adoptive cell transfer
- Cancer immunotherapy
- TCR/CAR T cells
- Macrophage cellular phagocytosis
- Don't eat me signals
- Tumor-specific Monoclonal antibodies
- T cell engineering
- Thymopoiesis in vitro
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Ιατρική Βιοτεχνολογία
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
- Medical Biotechnology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52979